Pulling SEC filings + quote and writing the call…

Arcadia Biosciences, Inc.
Next earnings Aug 12, 2026 · consensus $-0.57 EPS, $1.94M rev
Last earnings +0.9% on 2026-05-14
Sub-$2M shell burning $4.7M/yr on $259K cash, with its oil-pivot reverse merger dead — a going-concern trap, not an investment.
Cash & equivalents $259K · FY2025
Arcadia is a $1.51M micro-cap husk whose entire forward thesis just evaporated. Management spent 2024–2025 dismantling the legacy wheat-trait business — selling the RS durum trait to Corteva ($4.0M) and the GoodWheat brand to Above Food ($3.7M) — then bet the company on an all-stock reverse merger with oil-and-gas partnership Roosevelt Resources that would have handed Roosevelt's limited partners 90% of the company. On December 24, 2025, Roosevelt terminated that Exchange Agreement. The 'Crude Petroleum & Natural Gas' SIC code is a fossil of a pivot that no longer exists; what remains is the Zola coconut-water business generating $4.86M of shrinking revenue (-3.7% YoY, and down from $7.42M in FY2022).
The balance sheet is the disqualifier. Cash fell 93.9% to just $259K while operating cash flow was -$4.74M for the year — the company burned roughly eighteen times its remaining cash and has no debt capacity story here, only equity. R&D has been cut to essentially nothing ($9K, -83%), confirming there is no product pipeline left to fund; this is a company in wind-down or desperate-recapitalization mode, not growth. Total assets collapsed 51.6% to $6.55M and stockholders' equity fell to $4.14M against a staggering -$281M accumulated deficit. Share count already rose 50.5% YoY to 2.06M, and the only realistic path to survival is further dilutive issuance or another merger of necessity — either of which transfers value away from today's holders.
Is RKDA a buy? The one-page verdict, explained →
AVOID means we wouldn't engage at all — if expressing the short side anyway, only with capped risk.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $6.78M | $7.42M | $4.45M | $5.04M | $4.86M |
| Gross profit | — | — | — | — | — |
| Operating income | -$35.5M | -$14.0M | -$6.10M | -$3.65M | -$2.50M |
| Net income | -$14.7M | -$15.4M | -$14.0M | -$7.04M | -$2.34M |
| Diluted EPS | -$27.56 | -$25.65 | -$11.29 | -$5.17 | -$1.71 |
| Net margin | -216.2% | -207.3% | -313.9% | -139.5% | -48.1% |
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Officer/director change plus shareholder-nomination notice and other events disclosed
Filed shelf registration — capacity for future dilutive capital raises
New material agreement and unregistered share sale — dilutive private placement
Q1 2026: cash down to ~$0.3M, going-concern doubt persists despite smaller loss
Q1 2026: cash down to ~$0.3M, going-concern doubt persists despite smaller loss
Amended FY2025 10-K (Part III/technical) — no financial restatement
Changed independent registered accountant — auditor switch
FY2025: Roosevelt merger terminated; loss narrowed but cash critically low
FY2025: Roosevelt merger terminated; loss narrowed but cash critically low
Sources: SEC EDGAR (CIK 0001469443, latest 10-Q filed 2026-05-14) · EODHD · Proprietary analysis · as of 7/4/2026, 10:36:53 AM.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 4, 2026, 6:36 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
| 2025-02-03 | Kawakami Mark Chief Financial Officer | Buy | 700.00 @ $2.49 | $1.74K |
| 2025-02-03 | Schaefer Thomas J. Chief Executive Officer | Buy | 700.00 @ $2.49 | $1.74K |
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
1195 tracked peers · median